Alzheimer's Research Advances and Hawaii's Legislative Action Take Center Stage at 2026 Brain Health Summit
核心洞察
The Alzheimer's Association Brain Health Summit in Hawaii highlighted new disease-modifying treatments, blood biomarker testing, and the importance of early detection for Alzheimer's disease (搜索).
Hawaii passed landmark legislation requiring cognitive screening during Medicare annual wellness visits and established the HANAI Memory Network Program to support dementia care.
Over 100,000 Hawaii residents are affected by Alzheimer's, and the state has the fifth fastest-growing Alzheimer's mortality rate nationwide.
The Alzheimer's Association Brain Health Summit, hosted by the University of Hawaii John A. Burns School of Medicine (搜索), convened over a hundred community members and healthcare professionals on Saturday to explore the latest advances in Alzheimer's research and care. The summit underscored a pivotal moment in the field, where new disease-modifying treatments, innovative diagnostic tools, and state-level policy reforms are converging to reshape the outlook for patients and families.
"The future of Alzheimer's care is changing," said LJ Duenas, executive director of the Alzheimer's Association Hawaii. "Today's summit demonstrated that there is real hope right here in Hawaii. Research is advancing at an unprecedented pace, and we want families here to know there are more resources, more treatments, and more reasons than ever to seek answers early."
The event featured presentations on recent Alzheimer's advancements, lifestyle factors that support cognitive health, new blood biomarker testing, advances in diagnosis, disease-modifying treatments now available for eligible patients, and the importance of early detection.
A New Era of Disease-Modifying Treatments
The treatment landscape for Alzheimer's disease (搜索) has undergone a fundamental transformation in recent years. After decades of relying on drugs that only addressed symptoms, a new class of treatments now targets the underlying biology of the disease. The turning point came in 2021 when the U.S. Food and Drug Administration granted accelerated approval for aducanumab, the first treatment shown to address the underlying biology of Alzheimer's in people living with early-stage disease. Although aducanumab was later discontinued, it paved the way for lecanemab and donanemab, both of which received traditional FDA approval.
These anti-amyloid therapies represent a significant scientific advance, but their potential benefit hinges on early diagnosis — made possible through timely cognitive screening. This connection between treatment efficacy and early detection was a central theme throughout the summit.
Hawaii's Legislative Response
Recognizing the urgency of early detection, Hawaii's state Legislature took decisive action. In 2025, lawmakers passed a law requiring healthcare providers to administer cognitive screening during Medicare annual wellness visits. Building on that momentum, in 2026 the Legislature passed a bill to establish the HANAI Memory Network Program, which supports early detection, clinical evaluation, care planning, and a continuum of dementia care through a memory clinic on Hawaii Island.
These policy measures carry particular weight given the state's disease burden. Over 100,000 Hawaii residents are affected by Alzheimer's disease (搜索), and Hawaii has the fifth fastest-growing Alzheimer's mortality rate nationwide.
Lifestyle Interventions and the U.S. POINTER Study
Beyond pharmacological advances, the summit highlighted the role of lifestyle interventions in preserving cognitive health. The Alzheimer's Association's U.S. POINTER study demonstrated that combining regular physical activity, cognitive exercise, health monitoring, and a brain-healthy diet can improve cognition and protect older adults from age-related decline in thinking and memory. While the study focused on older adults, experts emphasized that people of all ages can build cognitive reserve by practicing brain-healthy habits.
A 120-Year Journey
Alzheimer's disease (搜索) was first described in 1906 by Dr. Alois Alzheimer, who connected changes in memory and behavior with physical changes in the brain. In the 1980s, the founding of the Alzheimer's Association helped build research infrastructure, and scientists identified the hallmark pathologies of the disease: beta-amyloid (搜索) plaques and tau (搜索) tangles. By the 1990s, the first drugs to treat symptoms emerged. Now, more than 120 years after the disease was first characterized, the field stands at an inflection point.
"We have known about Alzheimer's disease (搜索) for more than 120 years, and there is still no cure. But this moment is different," said Dr. Nic Los Baños, Hawaii County program manager for the Alzheimer's Association — Hawaii. "Research is opening new doors, earlier detection is giving families more time to plan, and brain-health habits are reminding us that each of us has a role to play."
The summit concluded with a call to action, encouraging community members to learn about the 10 healthy habits for brain health and to participate in the 2026 Walk to End Alzheimer's Hawaii Island on Saturday, September 19, at Liliʻuokalani Gardens in Hilo.